LifeStance Q1 rev $252.6M (+24% YoY), net loss narrows to $34.2M; raises FY rev guidance

LifeStance Health Group, Inc.

Revenue $252.6M (+24% YoY); Center Margin $69.6M (27.6% of revenue, +28% YoY).
Net loss $34.2M vs $62.3M loss; Adj EBITDA $10.1M vs $12.5M (down 19%).
FY 2023 revenue guidance raised to $990M-$1.02B; Center Margin $274-$290M; Adj EBITDA reaffirmed $50-$62M.
Q2 2023 guidance: rev $250-$260M, Center Margin $69-$76M, Adj EBITDA $10-$16M.
Clinicians 5,961 (+19% YoY, net add 330); cash $68.3M, net debt $224.8M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LifeStance Health Group, Inc. reported the first quarter ended March 31, 2023 results: revenue $252.6 million, net income $34.2 million. Guidance raised.

Period: the first quarter ended March 31, 2023
Revenue: $252.6 million
Net income: $34.2 million
Guidance: raised
Result: reported results

Exact text from the filing

the first quarter ended March 31, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q1 2023 Highlights and FY 2023 Outlook • Total revenue of $252.6 million increased $49.5 million or 24% compared to revenue of $203.1 million • Total clinicians of 5,961 up 19%, a sequential net increase of 330 in the first quarter • Net loss of $34.2

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

LifeStance Health Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.